The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

Reconciliation of Gross Profit

	Second Quarter								
		2018	2017						
Reported (GAAP)	\$	398,717	\$	372,984					
Operational Improvement Initiatives (a)		403		445					
Acquisition Related Costs (b)		-		5,606					
Integration Related Costs (c)		-		98					
FDA Mandated Product Recall (g)		-		3,500					
Adjusted (Non-GAAP)	\$	399,120	\$	382,633					

Reconciliation of Selling and Administrative Expenses

	Second Quarter								
		2018		2017					
Reported (GAAP)	\$	157,407	\$	139,319					
Acquisition Related Costs (b)		4		(672)					
Integration Related Costs (c)		-		(542)					
Legal Charges/Credits, net (d)		-		(1,000)					
Tax Assessment (e)		-		19					
Frutarom Acquisition Related Costs (h)		(12,455)							
Adjusted (Non-GAAP)	\$	144,956	\$	137,124					

Reconciliation of Operating Profit

	Second Quarter						
		2018	2017				
Reported (GAAP)	\$	154,509	\$	151,687			
Operational Improvement Initiatives (a)		403		445			
Acquisition Related Costs (b)		(4)		6,278			
Integration Related Costs (c)		993		731			
Legal Charges/Credits, net (d)		-		1,000			
Tax Assessment (e)		-		(19)			
Restructuring and Other Charges, net (f)		193		791			
Losses (Gains) on Sale of Assets		1,264		(68)			
FDA Mandated Product Recall (g)		-		3,500			
Frutarom Acquisition Related Costs (h)		12,455		-			
Adjusted (Non-GAAP)	\$	169,813	\$	164,345			

The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

Reconci	liation of	Net	Incom	е

	Second Quarte														
	2018							2017							
D (244P)		Income before		Taxes on		t income	EPS (j)	Income before		Taxes on	Net income	EPS			
		taxes	in	income (i)				taxes		income (i)					
Reported (GAAP)	\$	121,918	\$	22,769	\$	99,149	\$1.25	\$	142,040	\$ 32,245	\$ 109,795	\$1.38			
Operational Improvement Initiatives (a)		403		142		261	-		445	111	334	-			
Acquisition Related Costs (b)		(4)		(1)		(3)	-		6,278	1,472	4,806	0.06			
Integration Related Costs (c)		993		-		993	0.01		731	243	488	0.01			
Legal Charges/Credits, net (d)		-		-		-	-		1,000	354	646	0.01			
Tax Assessment (e)		-		-		-	-		(19)	(7)	(12)	-			
Restructuring and Other Charges, net (f)		193		46		147	-		791	(75)	866	0.01			
Losses (Gains) on Sale of Assets		1,264		263		1,001	0.01		(68)	(22)	(46)	-			
FDA Mandated Product Recall (g)		-		-		-	-		3,500	1,238	2,262	0.03			
Frutarom Acquisition Related Costs (h)		36,989		6,543		30,446	0.38		-						
Adjusted (Non-GAAP)	\$	161,756	\$	29,762	\$	131,994	\$1.66	\$	154,698	\$ 35,559	\$ 119,139	\$1.50			

- (a) For 2018, represents accelerated depreciation related to a plant relocation in India. For 2017, represents accelerated depreciation and idle labor costs in Hangzhou, China.
- (b) For 2017, represents the amortization of inventory "step-up" related to the acquisitions of David Michael, Fragrance Resources and PowderPure, included in cost of goods sold and transaction costs related to the acquisitions of David Michael, Fragrance Resources and PowderPure, included in Selling and administrative expenses.
- (c) For 2018, represents costs related to the integration of David Michael. For 2017, represents costs related to the integration of David Michael and Fragrance Resources acquisitions.
- (d) Represents additional charge related to litigation settlement.
- (e) Represents the reserve for payment of a tax assessment related to commercial rent for prior periods.
- (f) Represents severance costs related to the 2017 Productivity Program.
- (g) Represents management's best estimate of losses related to the previously disclosed FDA mandated recall.
- (h) Represents transaction-related costs and expenses related to the pending acquisition of Frutarom. Amount includes \$10.6 million of bridge loan commitment fees included in Interest expense, \$25.0 million mark-to-market loss adjustment on an interest rate derivative and an \$11.0 million mark-to-market gain adjustment on a foreign currency derivative, and \$12.5 million of transaction costs included in administrative expenses.
- (i) The income tax expense (benefit) on non-GAAP adjustments is computed in accordance with ASC 740 using the same methodology as the GAAP provision of income taxes. Income tax effects of non-GAAP adjustments are calculated based on the applicable statutory tax rate for each jurisdiction in which such charges were incurred, except for those items which are non-taxable for which the tax expense (benefit) was calculated at 0%. For second quarter of 2018, certain non-GAAP adjustments were subject to valuation allowances and therefore was calculated at 0%.
- (j) The sum of these items does not foot due to rounding.

The Company tracks the amount of amortization recorded on recent acquisitions in order to monitor its progress with respect to its Vision 2020 goals. The following amounts were recorded with respect to recent acquisitions: \$0.7M related to PowderPure, \$2.0M related to Fragrance Resources, \$1.1M related to David Michael, \$1.6M related to Ottens Flavors, and \$2.0M related to Lucas Meyer Cosmetics.

The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

Reconciliation of Gross Profit

	Second Quarter Year-to-Date						
		2018		2017			
Reported (GAAP)	\$	804,525	\$	736,066			
Operational Improvement Initiatives (a)		856		1,066			
Acquisition Related Costs (b)		-		10,907			
Integration Related Costs (c)		-		186			
FDA Mandated Product Recall (h)		5,000		3,500			
Adjusted (Non-GAAP)	\$	810,381	\$	751,725			

Reconciliation of Selling and Administrative Expenses

	Se	Second Quarter Year-to-D					
		2018		2017			
Reported (GAAP)	\$	300,051	\$	283,023			
Acquisition Related Costs (b)		518		(4,159)			
Integration Related Costs (c)		-		(1,485)			
Legal Charges/Credits, net (d)		-		(1,000)			
Tax Assessment (e)		-		(5,331)			
Frutarom Acquisition Related Costs (j)		(12,455)					
Adjusted (Non-GAAP)	\$	288,114	\$	271,048			

Reconciliation of Operating Profit

	Second Quarter Year-to-Date					
		2018		2017		
Reported (GAAP)	\$	329,363	\$	281,750		
Operational Improvement Initiatives (a)		1,429		1,066		
Acquisition Related Costs (b)		(518)		15,066		
Integration Related Costs (c)		993		1,923		
Legal Charges/Credits, net (d)		-		1,000		
Tax Assessment (e)		-		5,331		
Restructuring and Other Charges, net (f)		910		10,934		
Losses (Gains) on Sale of Assets		1,195		(89)		
FDA Mandated Product Recall (h)		5,000		3,500		
Frutarom Acquisition Related Costs (j)		12,455		_		
Adjusted (Non-GAAP)	\$	350,827	\$	320,481		

The following information and schedules provide reconciliation information between reported GAAP amounts and non-GAAP certain adjusted amounts. This information and schedules are not intended as, and should not be viewed as, a substitute for reported GAAP amounts or financial statements of the Company prepared and presented in accordance with GAAP.

Reconciliation of Net Income

	Second Quarter Year-to-Date											
				2018		2017						
	Income		Income Taxe before taxes incom		Net income	EPS	Income before taxes		Taxes on income (k)	Net income	EPS (I)	
Reported (GAAP)	9	280,754	\$	52,190	\$ 228,564	\$2.87	\$	280,527	\$ 54,968	\$ 225,559	\$2.84	
Operational Improvement Initiatives (a)	·	1,429	•	436	993	0.01	•	1,066	266	800	0.01	
Acquisition Related Costs (b)		(518)		(135)	(383)	-		15,066	4,610	10,456	0.13	
Integration Related Costs (c)		993		-	993	0.01		1,922	605	1,317	0.02	
Legal Charges/Credits, net (d)		-		-	-	-		1,000	354	646	0.01	
Tax Assessment (e)		-		-	-	-		5,331	1,885	3,446	0.04	
Restructuring and Other Charges, net (f)		910		215	695	0.01		10,934	2,892	8,042	0.10	
Losses (Gains) on Sale of Assets		1,195		246	949	0.01		(89)	(29)	(60)	-	
CTA Realization (g)		-		-	-	-		(12,214)	-	(12,214)	(0.15)	
FDA Mandated Product Recall (h)		5,000		1,196	3,804	0.05		3,500	1,238	2,262	0.03	
U.S. Tax Reform (i)		-		(649)	649	0.01		-	-	-	-	
Frutarom Acquisition Related Costs (j)		36,989		6,543	30,446	0.38		-	-	-	-	
Adjusted (Non-GAAP)	9	326,752	\$	60,042	\$ 266,710	\$3.35	\$	307,043	\$ 66,789	\$ 240,254	\$3.02	

- (a) For 2018, represents accelerated depreciation related to a plant relocation in India. For 2017, represents accelerated depreciation and idle labor costs in Hangzhou, China.
- (b) For 2018, represents adjustments to the contingent consideration payable for PowderPure, and transaction costs related to Fragrance Resources and PowderPure within Selling and administrative expenses. For 2017, represents the amortization of inventory "step-up" related to the acquisitions of David Michael, Fragrance Resources and PowderPure, included in cost of goods sold and transaction costs related to the acquisitions of David Michael, Fragrance Resources and PowderPure, included in Selling and administrative expenses.
- (c) For 2018, represents costs related to the integration of David Michael. For 2017, represents costs related to the integration of David Michael and Fragrance Resources acquisitions.
- (d) Represents additional charge related to litigation settlement.
- (e) Represents the reserve for payment of a tax assessment related to commercial rent for prior periods.
- (f) Represents severance costs related to the 2017 Productivity Program and Taiwan lab closure.
- (g) Represents the release of CTA related to the liquidation of a foreign entity.
- (h) Represents management's best estimate of losses related to the previously disclosed FDA mandated recall.
- (i) Represents charges incurred related to enactment of certain U.S. tax legislation changes in December 2017.
- (j) Represents transaction-related costs and expenses related to the pending acquisition of Frutarom. Amount includes \$10.6 million of bridge loan commitment fees included in Interest expense, \$25.0 million mark-to-market loss adjustment on an interest rate derivative and an \$11.0 million mark-to-market gain adjustment on a foreign currency derivative, and \$12.5 million of transaction costs included in administrative expenses.
- (k) The income tax expense (benefit) on non-GAAP adjustments is computed in accordance with ASC 740 using the same methodology as the GAAP provision of income taxes. Income tax effects of non-GAAP adjustments are calculated based on the applicable statutory tax rate for each jurisdiction in which such charges were incurred, except for those items which are non-taxable for which the tax expense (benefit) was calculated at 0%. For second quarter of 2018, certain non-GAAP adjustments were subject to valuation allowances and therefore was calculated at 0%.
- (I) The sum of these items does not foot due to rounding.
- The Company tracks the amount of amortization recorded on recent acquisitions in order to monitor its progress with respect to its Vision 2020 goals. The following amounts were recorded with respect to recent acquisitions: \$1.4M related to PowderPure, \$4.0M related to Fragrance Resources, \$2.3M related to David Michael, \$3.1M related to Ottens Flavors, and \$4.3M related to Lucas Meyer Cosmetics.